18.93
0.30 (1.61%)
| Previous Close | 18.63 |
| Open | 18.70 |
| Volume | 99,519 |
| Avg. Volume (3M) | 395,250 |
| Market Cap | 684,187,008 |
| Price / Sales | 5.47 |
| Price / Book | 2.46 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -62.50% |
| Operating Margin (TTM) | -69.33% |
| Diluted EPS (TTM) | -1.25 |
| Quarterly Revenue Growth (YOY) | 42.30% |
| Total Debt/Equity (MRQ) | 12.03% |
| Current Ratio (MRQ) | 17.36 |
| Operating Cash Flow (TTM) | -36.90 M |
| Levered Free Cash Flow (TTM) | -26.02 M |
| Return on Assets (TTM) | -17.46% |
| Return on Equity (TTM) | -41.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | CeriBell, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -4.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.30 |
|
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 10.54% |
| % Held by Institutions | 84.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Abg-Wtt Global Life Science Capital Partners Gp Ltd | 31 Mar 2025 | 1,088,101 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ROBERTSON REBECCA B | - | 11.61 | -827 | -9,601 |
| WOO RAYMOND | - | 12.33 | -11,112 | -137,011 |
| Aggregate Net Quantity | -11,939 | |||
| Aggregate Net Value ($) | -146,612 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.97 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WOO RAYMOND | Officer | 04 Sep 2025 | Automatic sell (-) | 11,112 | 12.33 | 137,011 |
| WOO RAYMOND | Officer | 04 Sep 2025 | Option execute | 11,112 | - | - |
| ROBERTSON REBECCA B | Director | 03 Sep 2025 | Automatic sell (-) | 827 | 11.61 | 9,601 |
| Date | Type | Details |
|---|---|---|
| 29 Jul 2025 | Announcement | Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference |
| 22 Jul 2025 | Announcement | Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025 |
| 07 Jul 2025 | Announcement | Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware |
| 20 Jun 2025 | Announcement | AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |